On Invalid Date, Calidi Biotherapeutics (NYSEMKT: CLDI) reported Q4 2023 earnings per share (EPS) of $0.25, up 127.47% year over year. Total Calidi Biotherapeutics earnings for the quarter were -$8.23 million. In the same quarter last year, Calidi Biotherapeutics's earnings per share (EPS) was -$0.91.
As of Q2 2024, Calidi Biotherapeutics's earnings has grown year over year. Calidi Biotherapeutics's earnings in the past year totalled -$29.22 million.
What is CLDI's earnings date?
Calidi Biotherapeutics's earnings date is Invalid Date. Add CLDI to your watchlist to be reminded of CLDI's next earnings announcement.
What was CLDI's revenue last quarter?
On Invalid Date, Calidi Biotherapeutics (NYSEMKT: CLDI) reported Q4 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Calidi Biotherapeutics's revenue was $0.00.
What was CLDI's revenue growth in the past year?
As of Q2 2024, Calidi Biotherapeutics's revenue has grown -100% year over year. This is 251.46 percentage points lower than the US Biotechnology industry revenue growth rate of 151.46%. Calidi Biotherapeutics's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.